Medication info

Linatone M Tablets 2.5/500mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Korea Pavis Pharmaceutical Co., Ltd.
Appearance
Bright yellow, biconvex, oval film-coated tablet
Packaging
60 tablets (10 tablets/PTP packaging) X 6
Approval status
Active

MFDS item code 201903570 · Approved 2019.05.30

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy and inadequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; this may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should take as the initial dose the same doses of linagliptin and metformin they were taking previously. 3. Patients with inadequate glycemic control on concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Do not Administer to the Following Patients).

Ingredients

Manufacturer
Korea Pavis Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in adult patients with type 2 diabetes. It is particularly effective in cases where control of blood glucose is difficult with monotherapy due to a lack of prior treatment experience. It is also administered when switching from a combination of linagliptin and metformin, or if blood sugar control is still insufficient after combination therapy with insulin and metformin. In cases where blood sugar is not adequately controlled with metformin and the maximum dose of empagliflozin, this medication can be used in combination with empagliflozin. This drug is used to improve blood sugar control under various therapeutic conditions.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy and inadequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; this may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should take as the initial dose the same doses of linagliptin and metformin they were taking previously. 3. Patients with inadequate glycemic control on concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral hypoglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Do not Administer to the Following Patients).

Precautions

This medication can cause a rare but serious side effect called lactic acidosis, so caution is required. Patients with allergies to the active ingredient or component of this medication, type 1 diabetes patients, patients with severe renal impairment, and certain other patients should not use this medication. If renal function is impaired, this medication should not be administered, and patients with unstable renal function should undergo regular renal function tests. Patients with weak heart function or those who have acute heart disease should also use this medication cautiously. If iodinated contrast media is required during radiological examinations, the use of this medication should be stopped before and after the examination, and it should only be resumed once renal function is stabilized. Patients scheduled for surgery should stop taking this medication 48 hours before the surgery and only resume after normal recovery of renal function. This medication may cause hypoglycemia, so when used in conjunction with insulin or sulfonylureas, blood sugar levels should be carefully monitored. If severe abdominal pain or signs of acute pancreatitis occur during use, the medication should be discontinued immediately and the physician should be consulted. If blisters or rashes develop on the skin while taking this medication, the physician should be informed immediately, and if blistering dermatitis is suspected, the medication should be stopped. Long-term use of this medication can lead to vitamin B12 deficiency, so regular checks of vitamin B12 levels are recommended. Pregnant women or women who may become pregnant, as well as nursing mothers, should avoid using this medication and should consult with a doctor for appropriate treatment if planning for pregnancy. It is not recommended for children under 10 years old and adolescents aged 10 to 17, as safety and efficacy have not been established. Elderly patients are commonly at risk for impaired renal function, so it is advisable to periodically check renal function and administer the minimum effective dose. The risk of lactic acidosis increases when this medication is taken with alcohol; therefore, it is important to avoid alcohol consumption. There may be drug interactions; thus, patients should inform their doctor or pharmacist of any other medications they are taking. Caution is required when driving or operating machinery during treatment, so patients should closely monitor their condition.

Side effects

Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, hypoglycemia, taste disorders, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, formation of oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular-like pemphigoid, severe joint pain accompanied by disability, rhabdomyolysis, increased lipase, increased amylase, constipation, epigastric pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, loss of appetite, dehydration, hyperglycemia, cerebral infarction, speech disorders, Alzheimer's dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage kidney disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, transplant rejection of the kidney, pneumonia, hypertension, pruritus, insomnia, depression, angina pectoris, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, viral upper respiratory tract infection, periodontitis, influenza, dyspepsia, gastritis, dizziness, drowsiness, discomfort in the chest, asthenia, pain, nosebleed, oropharyngeal pain, voice impairment, epistaxis, hearing loss, erectile dysfunction, goiter, disorientation, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, to maintain the effectiveness of the drug, it is recommended to store it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Bright yellow, biconvex, oval film-coated tablet

Package unit

60 tablets (10 tablets/PTP packaging) X 6

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.